In this application, we propose to address PQ10: As we improve methods to identify epigenetic changes that occur during tumor development, can we develop approaches to discriminate between driver and passenger epigenetic events?. Epigenetic mechanisms exert a strong effect on gene expression potential, and have been shown to undergo widespread change in most human cancers. In contrast to most mutational events, epigenetic events often display a high degree of correlation, with a large number of defined alterations that appear to be passenger events without functional contribution to the cancer process. We propose to develop an integrated computational and experimental validation pipeline to identify epigenetic driver events in cancer.
In Aim 1 we will develop a probabilistic framework for predicting and prioritizing candidate epigenetic driver loci. This approach is unique in that it fully integrates the wealth of available data, using complementary data types derived from primary genomic data, experimental data, and supporting curated information, resulting in a composite Epigenetic Driver Score (EDS), reflecting the posterior probability that each gene is an epigenetic driver.
Aim 2 will provide experimental data on epigenetic addiction, using cell lines depleted of DNA methyltransferases, and thus selected to retain only the most essential silencing events, in addition to data obtained with embryonic and adult stem-cell and progenitors. These experimental data sets will be used to complement primary epigenomic data we have generated in the context of TCGA, to provide Epigenetic Driver Scores for each locus in each tumor type, using the methodology developed in Aim 1.
In Aim 3 a we will functionally test the top-ranked candidate epigenetic drivers of colon, breast, and lung cancer in vitro, by reintroducing expression of candidate genes into appropriate human cancer cells lines containing the relevant silencing events. These experiments will be complemented by shRNA approaches in cell lines to modulate the functional expression of the candidate epigenetic drivers. In vitro proliferation and apoptosis assays will be used to assess phenotypic effects.
In Aim 3 b we will assess the functional contributions of the candidate epigenetic drivers in vivo, using the stable cell lines created in Aim 3a in xenograft mouse models. The results of these validation experiments will be used to iteratively train the EDS model. Given the sensitivity of learning algorithms to their training data, we anticipate an improvement in performance as the number of training examples increases. By performing data-driven modeling in a probabilistic framework and computationally- directed experimentation the available data will be utilized to the fullest extent, while allowing for the addition of new data types and expert curation. The role of epigenetic events in cancer is increasingly appreciated, but the challenge of distinguishing drivers from passengers has not yet been adequately addressed. The systematic validation pipeline proposed here will address a large unmet need, and yield insights into the complementary roles of epigenetic and genetic events in key signaling pathways that drive tumorigenesis.

Public Health Relevance

Cancer arises from loss of the growth control of cells. Although most attention has focused on genetic mutations as the origin of these defects, in recent years, it has become increasingly appreciated that changes in the epigenetic control of gene activity also contribute to this loss of growth control. This application addresses an unmet need to develop methods of finding out which epigenetic changes contribute directly to cancer formation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA170550-04
Application #
9039821
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Tarnuzzer, Roy W
Project Start
2012-09-01
Project End
2017-06-30
Budget Start
2015-07-01
Budget End
2017-06-30
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Van Andel Research Institute
Department
Type
DUNS #
129273160
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Zhou, Wanding; Dinh, Huy Q; Ramjan, Zachary et al. (2018) DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat Genet 50:591-602
Xie, Wenbing; Kagiampakis, Ioannis; Pan, Lixia et al. (2018) DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk. Cancer Cell 33:309-321.e5
Xia, Limin; Huang, Wenjie; Bellani, Marina et al. (2017) CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes. Cancer Cell 31:653-668.e7
Vaz, Michelle; Hwang, Stephen Y; Kagiampakis, Ioannis et al. (2017) Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell 32:360-376.e6
Zhang, Yang W; Wang, Zhihong; Xie, Wenbing et al. (2017) Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. Mol Cell 65:323-335
Zhou, Wanding; Laird, Peter W; Shen, Hui (2017) Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res 45:e22
Charlet, Jessica; Duymich, Christopher E; Lay, Fides D et al. (2016) Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. Mol Cell 62:422-431
Becket, Elinne; Chopra, Sameer; Duymich, Christopher E et al. (2016) Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. Cancer Res 76:1954-64
Lee, Kwang-Ho; Laird, Peter W (2016) All Things in Moderation: Prevention of Intestinal Adenomas by DNA Hypomethylation. Cancer Prev Res (Phila) 9:509-11
Roulois, David; Loo Yau, Helen; Singhania, Rajat et al. (2015) DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162:961-73

Showing the most recent 10 out of 17 publications